Selective Estrogen Receptor Modulator: Raloxifene

Journal of Reproduction and Contraception

Volumn 22, Issue 1, 2011, Pages 51-60

  Dai, Xue ^a   Wu, Jie ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Estrogen agonists; Estrogen antagonists; Raloxifene; Selective estrogen receptor modulator (SERM)

Indexed keywords

RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; DRUG MECHANISM; DRUG RECEPTOR BINDING; ESTROGEN ACTIVITY; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; VERTEBRA FRACTURE;

EID: 84863011241     PISSN: 10017844     EISSN: 18767966     Source Type: Journal    
DOI: 10.1016/S1001-7844(12)60007-8     Document Type: Review

References (49)

1. Cho CH, Nuttall ME Therapeutic potential of oestrogen receptor ligands in development for osteoporosis. Expert Opin Emerg Drugs 2001, 6(1):137-154.
2. Gennari L Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs Today (Barc) 2006, 42(6):355-367.
3. Ramaswamy B, Majumder S, Roy S, et al. Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity. Mol Endocrinol 2009, 23(2):176-187.
4. Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for antiestrogen resistance. J Biol Chem 2001, 276(13):9817-9824.
5. Font de Mora J, Brown M AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000, 20(14):5041-5047.
6. Wijavaratne AL, McDonnell DP The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 2001, 276(38):35684-35692.
7. Smith CL, O'Malley BW Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004, 25(1):45-71.
8. Jordan VC Selective estrogen receptor modulation: a personal perspective. Cancer Res 2001, 61(15):5683-5687.
9. Bouxsein ML, Chen P, Glass EV, et al. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials. J Bone Joint Surg Am 2009, 91(6):1329-1338.
10. Brennan TC, Rizzoli R, Ammann P Selective modification of bone quality by PTH, pamidronate, or raloxifene. J Bone Miner Res 2009, 24(5):800-808.
11. Lim SK, Won YJ, Lee HC, et al. A PCR analysis of ERalpha and ERbeta mRNA abundance in rats and the effect of ovariectomy. J Bone Miner Res 1999, 14(7):1189-1196.
12. Hou NN, Zhu YM, Huang HF The expression of estrogen receptor alpha and beta in the intervention of different estrogens in rat bone metabolism. Chin J Biochem Mol Biol (in Chinese) 2006, 39(4):289-296.
13. Ozmen B, Kirmaz C, Aydin K, et al. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw 2007, 18(3):148-153.
14. Li RX, Xiao XR, Gu C, et al. Effect of p38MAPK inhibition on receptor activator of nuclear factor-KB ligand and osteoprotegerin expressions in osteoblasts. Fudan Univ J Med Sci (in Chinese) 2010, 37(1):39-42.
15. Jochems C, Lagerquist M, Hakansson C, et al. Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis. Clin Exp Immunol 2008, 152(3):593-597.
16. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3 year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282(7):637-645.
17. Ensrud KE, Stock JL, Barrett-Connor E, et al. Effects of raloxifene on fracture risk in postmenopausal women: the raloxifene use for the heart trial. J Bone Miner Res 2008, 23(1):112-120.
18. da Silva BB, Moita DS, Pires CG, et al. Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene. Int Semin Surg Oncol 2007, 4:18.
19. da Silva BB, dos Santos AR, Pires CG, et al. Effect of raloxifene on vascular endothelial growth factor expression in breast carcinomas of postmenopausal women. Cell Prolif 2009, 42(4):506-510.
20. da Silva BB, Pires CG, dos Santos AR, et al. Effects of raloxifene on Ki-67 and CD34 antigen expression in breast cancer. Gynecol Obstet Invest 2009, 67(2):103-108.
21. Deng WH, Tang WQ, Wang S, et al. The effects of raloxifene and estradiol benzoate on expression of estrogen sulfotransferase in human breast tissues implanted into nude mice. Reprod Med 2009, 18(3):1544-1547. (in Chinese).
22. Cummings SR, Eckert S, Kreuger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized tria. JAMA 1999, 281(23):2189-2197.
23. Lee WL, Chao HT, Cheng MH, et al. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas 2008, 60(2):92-107.
24. Vogel VG The NSABP study of tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 2009, 9(1):51-60.
25. Lasco A, Gaudio A, Morini E, et al. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women. Menopause 2006, 13(5):787-792.
26. Johnston CC, Bjamason NH, Cohen FJ, et al. Longterm effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal menopausal women: three-year data from 2 doubleblind, randomized, placebo-controlled trials. Arch Intern Med 2000, 160(22):3444-3450.
27. Colacurci N, Fornaro F, Cobellis L, et al. Raloxifene slows down the progression of intima-media thickness in postmenopausal women. Menopause 2007, 14(5):879-884.
28. Oktem M, Atar I, Zeyneloqlu HB, et al. Raloxifene has favourable effects on metabolic parameters but has no effect on left ventricular function in postmenopausal women. Pharmacol Res 2008, 57(5):364-368.
29. Adomaityte J, Farooq M, Qayyum R Effect of raloxifene therapy on venous thromboembolism in post-menopausal women. A meta-analysis. Thromb Haemost 2008, 99(2):338-342.
30. Mosca L, Grady D, Barrett-Connor E, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009, 40(1):147-155.
31. Minamitani C, Takai S, Matsushima-Nishiwaki R, et al. Raloxifene-induced acceleration of platelet aggregation. Intern Med 2008, 47(17):1523-1528.
32. Abu-Fanne R, Brzezinski A, Golomb M, et al. Effects of estradiol and raloxifene on arterial thrombosis in ovariectomized mice. Menopause 2008, 15(1):98-104.
33. Choi BG, Vilahur G, Zafar MU, et al. Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. Atherosclerosis 2008, 201(1):76-84.
34. Yu J, Eto M, Kozaki K, et al. Raloxifene analogue LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway. Eur Pharmacol 2008, 589(1-3):32-36.
35. He H, Zhu H, Yang FL, et al. Effects of raloxifene on the ERE transcription activity and its relationship with estrogen receptor subtypes in vascular endothelial cells. J Shandong Univ (Health Science)(in Chinese) 2004, 42(5):555-557.
36. Tapia-Gonzalez S, Carrero P, Pernia O, et al. Selective oestrogen receptor (ER) modulators reduce microglia reactivity in vivo after peripheral inflammation: potential role of microglial ERs. J Endocrinol 2008, 198(1):219-230.
37. Bebo BF, Dehghani B, Foster S, et al. Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis. Glia 2009, 57(7):777-790.
38. Cerciat M, Unkila M, Garcia-Segura LM, et al. Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro. Glia 2010, 58(1):93-102.
39. Karahancer M, Cirpan T, Kanit L, et al. The effects of raloxifen on depression and cognition in ovariectomized rats. Fertil Steril 2008, 89(1):240-242.
40. Wu J, Zhu Y, Wu J Effects of estrogen and estrogenic compounds on cognition in ovariectomized rats. Climacteric 2008, 11(3):212-220.
41. Guvenal T, Durna A, Erden O, et al. Effects of different postmenopausal hormone therapy regimens on cerebral blood flow and cognitive functions. Adv Ther 2009, 26(8):805-811.
42. Zhang YX, Kong CZ The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment. National Medical Journal of China (in Chinese) 2008, 88(4):271-275.
43. Nomura H, Kawashima H, Masaki S, et al. Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithelial cells. Prostate Cancer Prostatic Dis 2009, 12(4):375-381.
44. Morishima S, Shibata MA, Ohmichi M, et al. Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells. Med Mol Morphol 2008, 41(3):132-138.
45. Premkumar A, Venzon DJ, Avila N, et al. Gynecologic and hormonal effects of raloxifene in premenopausal women. Fertil Steril 2007, 88(6):1637-1644.
46. Takeda T, Masuhara K, Kamiura S Successful management of a leiomyomatosis peritonealis disseminata with an aromatase inhibitor. Obstet Gynecol 2008, 112(2 Pt2):491-493.
47. Biri A, Korucuoglu U, Ilhan MN, et al. Evaluation of the sexual function and quality of life in raloxifene treated postmenopausal women. Arch Gynecol Obstet 2009, 279(4):505-509.
48. Delmanto A, Nahas-Neto J, Nahas EA, et al. Effect of raloxifene on the vaginal epithelium of postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2008, 139(2):187-192.
49. Snyder KR, Sparano N, Malinowski JM Raloxifene hydrochloride. Am J Health Syst Pharm 2000, 57(18):1669-1675.